The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Primary CD56+ NK Cells Market Research Report 2024
Synopsis
Primary CD56+ Natural killer (NK) cells are the major effectors of the innate immune system and are important in host defense, cancer, and autoimmunity. CD56+ Natural Killer Cells are isolated from mononuclear cells by negative selection using immunomagnetic cell separation procedures.
Global Primary CD56+ NK Cells market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Primary CD56+ NK Cells market research.
Key manufacturers engaged in the Primary CD56+ NK Cells industry include PBM, ATCC, STEMCEITM, Thermo Fisher Scientific, AllCells, ABM, 3H Biomedical, ProMab Biotechnologies and AcceGen, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Primary CD56+ NK Cells were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Primary CD56+ NK Cells market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Primary CD56+ NK Cells market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
PBM
ATCC
STEMCEITM
Thermo Fisher Scientific
AllCells
ABM
3H Biomedical
ProMab Biotechnologies
AcceGen
AMSBIO
Clinisciences
Creative Bioarray
iCell Bioscience
Shenzhen Kingfocus Biomedical
Segment by Type
Custom Made
Bulk
Segment by Application
Compound Screening
Immune Function Assay
Drug Discovery
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Primary CD56+ NK Cells report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Primary CD56+ Natural killer (NK) cells are the major effectors of the innate immune system and are important in host defense, cancer, and autoimmunity. CD56+ Natural Killer Cells are isolated from mononuclear cells by negative selection using immunomagnetic cell separation procedures.
Global Primary CD56+ NK Cells market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Primary CD56+ NK Cells market research.
Key manufacturers engaged in the Primary CD56+ NK Cells industry include PBM, ATCC, STEMCEITM, Thermo Fisher Scientific, AllCells, ABM, 3H Biomedical, ProMab Biotechnologies and AcceGen, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Primary CD56+ NK Cells were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Primary CD56+ NK Cells market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Primary CD56+ NK Cells market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
PBM
ATCC
STEMCEITM
Thermo Fisher Scientific
AllCells
ABM
3H Biomedical
ProMab Biotechnologies
AcceGen
AMSBIO
Clinisciences
Creative Bioarray
iCell Bioscience
Shenzhen Kingfocus Biomedical
Segment by Type
Custom Made
Bulk
Segment by Application
Compound Screening
Immune Function Assay
Drug Discovery
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Primary CD56+ NK Cells report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Primary CD56+ NK Cells Market Overview
1.1 Product Overview and Scope of Primary CD56+ NK Cells
1.2 Primary CD56+ NK Cells Segment by Type
1.2.1 Global Primary CD56+ NK Cells Market Value Comparison by Type (2023-2029)
1.2.2 Custom Made
1.2.3 Bulk
1.3 Primary CD56+ NK Cells Segment by Application
1.3.1 Global Primary CD56+ NK Cells Market Value by Application: (2023-2029)
1.3.2 Compound Screening
1.3.3 Immune Function Assay
1.3.4 Drug Discovery
1.3.5 Others
1.4 Global Primary CD56+ NK Cells Market Size Estimates and Forecasts
1.4.1 Global Primary CD56+ NK Cells Revenue 2018-2029
1.4.2 Global Primary CD56+ NK Cells Sales 2018-2029
1.4.3 Global Primary CD56+ NK Cells Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Primary CD56+ NK Cells Market Competition by Manufacturers
2.1 Global Primary CD56+ NK Cells Sales Market Share by Manufacturers (2018-2023)
2.2 Global Primary CD56+ NK Cells Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Primary CD56+ NK Cells Average Price by Manufacturers (2018-2023)
2.4 Global Primary CD56+ NK Cells Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Primary CD56+ NK Cells, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Primary CD56+ NK Cells, Product Type & Application
2.7 Primary CD56+ NK Cells Market Competitive Situation and Trends
2.7.1 Primary CD56+ NK Cells Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Primary CD56+ NK Cells Players Market Share by Revenue
2.7.3 Global Primary CD56+ NK Cells Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Primary CD56+ NK Cells Retrospective Market Scenario by Region
3.1 Global Primary CD56+ NK Cells Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Primary CD56+ NK Cells Global Primary CD56+ NK Cells Sales by Region: 2018-2029
3.2.1 Global Primary CD56+ NK Cells Sales by Region: 2018-2023
3.2.2 Global Primary CD56+ NK Cells Sales by Region: 2024-2029
3.3 Global Primary CD56+ NK Cells Global Primary CD56+ NK Cells Revenue by Region: 2018-2029
3.3.1 Global Primary CD56+ NK Cells Revenue by Region: 2018-2023
3.3.2 Global Primary CD56+ NK Cells Revenue by Region: 2024-2029
3.4 North America Primary CD56+ NK Cells Market Facts & Figures by Country
3.4.1 North America Primary CD56+ NK Cells Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Primary CD56+ NK Cells Sales by Country (2018-2029)
3.4.3 North America Primary CD56+ NK Cells Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Primary CD56+ NK Cells Market Facts & Figures by Country
3.5.1 Europe Primary CD56+ NK Cells Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Primary CD56+ NK Cells Sales by Country (2018-2029)
3.5.3 Europe Primary CD56+ NK Cells Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Primary CD56+ NK Cells Market Facts & Figures by Country
3.6.1 Asia Pacific Primary CD56+ NK Cells Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Primary CD56+ NK Cells Sales by Country (2018-2029)
3.6.3 Asia Pacific Primary CD56+ NK Cells Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Primary CD56+ NK Cells Market Facts & Figures by Country
3.7.1 Latin America Primary CD56+ NK Cells Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Primary CD56+ NK Cells Sales by Country (2018-2029)
3.7.3 Latin America Primary CD56+ NK Cells Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Primary CD56+ NK Cells Market Facts & Figures by Country
3.8.1 Middle East and Africa Primary CD56+ NK Cells Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Primary CD56+ NK Cells Sales by Country (2018-2029)
3.8.3 Middle East and Africa Primary CD56+ NK Cells Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Primary CD56+ NK Cells Sales by Type (2018-2029)
4.1.1 Global Primary CD56+ NK Cells Sales by Type (2018-2023)
4.1.2 Global Primary CD56+ NK Cells Sales by Type (2024-2029)
4.1.3 Global Primary CD56+ NK Cells Sales Market Share by Type (2018-2029)
4.2 Global Primary CD56+ NK Cells Revenue by Type (2018-2029)
4.2.1 Global Primary CD56+ NK Cells Revenue by Type (2018-2023)
4.2.2 Global Primary CD56+ NK Cells Revenue by Type (2024-2029)
4.2.3 Global Primary CD56+ NK Cells Revenue Market Share by Type (2018-2029)
4.3 Global Primary CD56+ NK Cells Price by Type (2018-2029)
5 Segment by Application
5.1 Global Primary CD56+ NK Cells Sales by Application (2018-2029)
5.1.1 Global Primary CD56+ NK Cells Sales by Application (2018-2023)
5.1.2 Global Primary CD56+ NK Cells Sales by Application (2024-2029)
5.1.3 Global Primary CD56+ NK Cells Sales Market Share by Application (2018-2029)
5.2 Global Primary CD56+ NK Cells Revenue by Application (2018-2029)
5.2.1 Global Primary CD56+ NK Cells Revenue by Application (2018-2023)
5.2.2 Global Primary CD56+ NK Cells Revenue by Application (2024-2029)
5.2.3 Global Primary CD56+ NK Cells Revenue Market Share by Application (2018-2029)
5.3 Global Primary CD56+ NK Cells Price by Application (2018-2029)
6 Key Companies Profiled
6.1 PBM
6.1.1 PBM Corporation Information
6.1.2 PBM Description and Business Overview
6.1.3 PBM Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.1.4 PBM Primary CD56+ NK Cells Product Portfolio
6.1.5 PBM Recent Developments/Updates
6.2 ATCC
6.2.1 ATCC Corporation Information
6.2.2 ATCC Description and Business Overview
6.2.3 ATCC Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.2.4 ATCC Primary CD56+ NK Cells Product Portfolio
6.2.5 ATCC Recent Developments/Updates
6.3 STEMCEITM
6.3.1 STEMCEITM Corporation Information
6.3.2 STEMCEITM Description and Business Overview
6.3.3 STEMCEITM Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.3.4 STEMCEITM Primary CD56+ NK Cells Product Portfolio
6.3.5 STEMCEITM Recent Developments/Updates
6.4 Thermo Fisher Scientific
6.4.1 Thermo Fisher Scientific Corporation Information
6.4.2 Thermo Fisher Scientific Description and Business Overview
6.4.3 Thermo Fisher Scientific Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Thermo Fisher Scientific Primary CD56+ NK Cells Product Portfolio
6.4.5 Thermo Fisher Scientific Recent Developments/Updates
6.5 AllCells
6.5.1 AllCells Corporation Information
6.5.2 AllCells Description and Business Overview
6.5.3 AllCells Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.5.4 AllCells Primary CD56+ NK Cells Product Portfolio
6.5.5 AllCells Recent Developments/Updates
6.6 ABM
6.6.1 ABM Corporation Information
6.6.2 ABM Description and Business Overview
6.6.3 ABM Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.6.4 ABM Primary CD56+ NK Cells Product Portfolio
6.6.5 ABM Recent Developments/Updates
6.7 3H Biomedical
6.6.1 3H Biomedical Corporation Information
6.6.2 3H Biomedical Description and Business Overview
6.6.3 3H Biomedical Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.4.4 3H Biomedical Primary CD56+ NK Cells Product Portfolio
6.7.5 3H Biomedical Recent Developments/Updates
6.8 ProMab Biotechnologies
6.8.1 ProMab Biotechnologies Corporation Information
6.8.2 ProMab Biotechnologies Description and Business Overview
6.8.3 ProMab Biotechnologies Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.8.4 ProMab Biotechnologies Primary CD56+ NK Cells Product Portfolio
6.8.5 ProMab Biotechnologies Recent Developments/Updates
6.9 AcceGen
6.9.1 AcceGen Corporation Information
6.9.2 AcceGen Description and Business Overview
6.9.3 AcceGen Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.9.4 AcceGen Primary CD56+ NK Cells Product Portfolio
6.9.5 AcceGen Recent Developments/Updates
6.10 AMSBIO
6.10.1 AMSBIO Corporation Information
6.10.2 AMSBIO Description and Business Overview
6.10.3 AMSBIO Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.10.4 AMSBIO Primary CD56+ NK Cells Product Portfolio
6.10.5 AMSBIO Recent Developments/Updates
6.11 Clinisciences
6.11.1 Clinisciences Corporation Information
6.11.2 Clinisciences Primary CD56+ NK Cells Description and Business Overview
6.11.3 Clinisciences Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Clinisciences Primary CD56+ NK Cells Product Portfolio
6.11.5 Clinisciences Recent Developments/Updates
6.12 Creative Bioarray
6.12.1 Creative Bioarray Corporation Information
6.12.2 Creative Bioarray Primary CD56+ NK Cells Description and Business Overview
6.12.3 Creative Bioarray Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Creative Bioarray Primary CD56+ NK Cells Product Portfolio
6.12.5 Creative Bioarray Recent Developments/Updates
6.13 iCell Bioscience
6.13.1 iCell Bioscience Corporation Information
6.13.2 iCell Bioscience Primary CD56+ NK Cells Description and Business Overview
6.13.3 iCell Bioscience Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.13.4 iCell Bioscience Primary CD56+ NK Cells Product Portfolio
6.13.5 iCell Bioscience Recent Developments/Updates
6.14 Shenzhen Kingfocus Biomedical
6.14.1 Shenzhen Kingfocus Biomedical Corporation Information
6.14.2 Shenzhen Kingfocus Biomedical Primary CD56+ NK Cells Description and Business Overview
6.14.3 Shenzhen Kingfocus Biomedical Primary CD56+ NK Cells Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Shenzhen Kingfocus Biomedical Primary CD56+ NK Cells Product Portfolio
6.14.5 Shenzhen Kingfocus Biomedical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Primary CD56+ NK Cells Industry Chain Analysis
7.2 Primary CD56+ NK Cells Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Primary CD56+ NK Cells Production Mode & Process
7.4 Primary CD56+ NK Cells Sales and Marketing
7.4.1 Primary CD56+ NK Cells Sales Channels
7.4.2 Primary CD56+ NK Cells Distributors
7.5 Primary CD56+ NK Cells Customers
8 Primary CD56+ NK Cells Market Dynamics
8.1 Primary CD56+ NK Cells Industry Trends
8.2 Primary CD56+ NK Cells Market Drivers
8.3 Primary CD56+ NK Cells Market Challenges
8.4 Primary CD56+ NK Cells Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
